- Home
- RCKT
as 05-30-2025 2:41pm EST
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 764.5M | IPO Year: | N/A |
| Target Price: | $21.77 | AVG Volume (30 days): | 7.1M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.19 - $26.98 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Rocket Pharmaceuticals Inc. News
RCKT Breaking Stock News: Dive into RCKT Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Evercore ISI Downgrades Rocket Pharmaceuticals to In Line From Outperform, $5 Price Target
MT Newswires
3 days ago
JPMorgan Downgrades Rocket Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $7 From $44
Insider Monkey
4 days ago
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow
Benzinga
4 days ago
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Insider Monkey
4 days ago
William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback
Zacks
4 days ago
RCKT Stock Tanks on Patient Death in Danon Disease Study
MT Newswires
4 days ago
Chardan Cuts Price Target on Rocket Pharmaceuticals to $17 From $46, Keeps Buy Rating
MT Newswires
4 days ago
Jefferies Downgrades Rocket Pharmaceuticals to Hold From Buy, Adjusts Price Target to $2.50 From $29
Compare RCKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RCKT Rocket Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.